Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

Apellis Pharmaceuticals’ (APLS Quick QuoteAPLS - Free Report) marketed portfolio comprises two drugs — Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection).

Zacks 36minutes ago

Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $49

Mizuho Securities analyst Graig Suvannavejh maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $52 to $49.According to TipRanks data, the analyst has a

Futu NewsJul 1 23:32 · Ratings

Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $49 From $52

BreakingsJul 1 12:53

BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $82

BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of

Futu NewsJun 29 21:32 · Ratings

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading

Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)

MT NewswiresJun 29 02:07

Apellis Pharmaceuticals Price Target Maintained With a $100.00/Share by Baird

Apellis Pharmaceuticals Price Target Maintained With a $100.00/Share by Baird

Dow JonesJun 29 01:20